Clinical trials: Cervical Pregnancy
Low Anterior Resection Syndrome, Malignant Anal Neoplasm
Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
This phase II trial studies how well sacral nerve stimulation works in treating low anterior resection syndrome or fecal incontinence (the body's passage of stool without control) in patients with rectal cancer that has spread to…
- Conditions
- Low Anterior Resection Syndrome, Malignant Anal Neoplasm, Malignant Bladder Neoplasm, Malignant Cervical Neoplasm
- Trial name
- NCT04066894
- Testing
- Explantation, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
CIN3, CIN2
Cervical Cancer Screening With Human Papillomavirus Testing
HPV testing for primary cervical cancer screening of women over 30 years of age is likely to become the standard of care in the near future in many areas of the world.
- Conditions
- CIN3, CIN2, Cervical Cancer
- Trial name
- ESTAMPA (NCT01881659)
- Testing
- HPV screening
- Where
- 12 sites in Argentina, Bolivia and 7 more
- Volunteers
- 50,000 people
- Sponsor
- International Agency for Research on Cancer
Cervical Cancer
Measurement of Digital Colposcopy for Fluorescence Spectroscopy of Cervical Intraepithelial Neoplasia
The overall objective of this study is to identify potential improvements for a noninvasive method of diagnosing dysplasia and neoplasia in the cervix using digital colposcopy for colposcopy for fluorescence spectroscopy.
- Trial name
- NCT00513123
- Testing
- Colposcopy
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer, Breast Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors
RATIONALE: The LMB-9 immunotoxin may be able to locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced solid tumors.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00019435
- Testing
- LMB-9 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Uterine Cervical Incompetence
Dilapan-S Osmotic Dilator in Pre-induction of Labor
Non-interventional prospective data collection designed to evaluate clinical outcome on the efficacy of the use of Dilapan-S in the indication of labor pre-induction in women with/without a history of Caesarean section.
- Trial name
- NCT02098382
- Testing
- Dilapan-S
- Where
- Czechia
- Volunteers
- 125 people
- Sponsor
- Medicem International CR s.r.o.
Endometrial Cancer, Ovarian Cancer
AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies
The purpose of this research study is to determine the safety of the combination of the two drugs cediranib and temsirolimus and the highest doses of these two drugs that can be given in combination to people safely.
- Conditions
- Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Fallopian Tube Cancer
- Trial name
- NCT01065662
- Testing
- temsirolimus, cediranib
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Susana M. Campos, MD
Cervical Cancer
Sentinel Concept in Early Stage Cervical Cancer
Aim of present study is to inspect, if the removal alone of sentinel lymph nodes in women with early Cervix Carcinoma lead to, at equal length, overall survival like entire systematic dissection of lymph node and at the same time…
- Trial name
- NCT01157962
- Testing
- Lymphadenectomy in cervical cancer
- Where
- Germany
- Volunteers
- 1,600 people
- Sponsor
- Charite University, Berlin, Germany
Sarcoma, Ovarian Neoplasm
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of pembrolizumab monotherapy in 7 cohorts of patients with specific rare cancers who have unresectable locally advanced or…
- Conditions
- Sarcoma, Ovarian Neoplasm, Central Nervous System Neoplasm, Thyroid Neoplasm
- Trial name
- AcSé (NCT03012620)
- Testing
- Pembrolizumab
- Where
- France
- Volunteers
- 334 people
- Sponsor
- UNICANCER
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
- Trial name
- NCT00082823
- Testing
- ziv-aflibercept
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Cervical Cancer
Self-sampling for Non-participants in an Organised Cervical Cancer Screening Programme
The trial will evaluate the effect on participation in organised screening programme of a human papilloma virus (HPV) self-sampling kit directly mailed home or mailed on demand compared with the standard second reminder for…
- Trial name
- CHOiCE (NCT02680262)
- Testing
- HPV self-sampling kit mailed directly, HPV self-sampling kit on demand, Second reminder
- Where
- Denmark
- Volunteers
- 9,327 people
- Sponsor
- University of Aarhus
Cervical Cancer, Endometrial Cancer
Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy
This randomized, pilot phase I trial studies whether phone or email reminders increases vaginal dilator use in patients with endometrial, cervical, or vaginal cancers after they undergo brachytherapy.
- Conditions
- Cervical Cancer, Endometrial Cancer, Radiation Toxicity, Vaginal Cancer
- Trial name
- NCT02058550
- Testing
- survey administration, computer-assisted intervention, telephone-based intervention
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Stanford University
TILs, Metastatic or Recurrent Cervical Cancer
TILs for Treatment of Metastatic or Recurrent Cervical Cancer
Prospective, single center, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion followed by IL-2 after a non-myeloablative (NMA)…
- Trial name
- NCT04674488
- Testing
- TILs
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai OriginCell Therapeutics Co., Ltd.
Genital Neoplasms, Female
Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies
The purpose of this clinical trial is to evaluate the effectiveness and safety of oncolytic viruses H101 intra-tumor injection combined with or without radiotherapy in refractory or recurrent gynecological malignancies.
- Trial name
- NCT05051696
- Testing
- H101
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Liu Zi
HPV16 Positive, Cervical Intraepithelial Neoplasia (CIN 2/3)
Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
This study will test the efficacy and safety of different routes of administration of a DNA vaccine in patients with HPV16+ CIN2/3. Subjects will be enrolled in one of six treatment groups.
- Trial name
- NCT00988559
- Testing
- DNA vaccination, Gene gun vaccine, intramuscular vaccination
- Where
- 3 sites in United States
- Volunteers
- 132 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cervical Cancers
Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT).
This is a prospective non-randomized clinical trial to evaluate the feasibility of 3 fraction versus a standard 4 fraction high dose rate brachytherapy regimen in patients with locally advanced cervical cancer.
- Trial name
- NCT07022470
- Testing
- 3-Fraction HDR Brachytherapy, 4-Fraction HDR Brachytherapy
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Stanford University
Cervical Cancer
Testing an Implementation Science Tool to Increase Cervical Cancer Screening in Mombasa, Kenya
Cervical cancer is the most common cancer in women in sub-Saharan Africa, and the majority of cervical cancer mortality occur in low and middle income countries (LMICs).
- Trial name
- NCT03514459
- Testing
- Systems Analysis and Improvement Approach
- Where
- Kenya
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Washington
Cancer of the Cervix
Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer Patients
The researchers plan: To undertake clinical studies of radiotherapy with or without the administration of the chemotherapeutic agent cisplatin, known to be a radiosensitizer; To perform pre-clinical studies of the…
- Trial name
- NCT00122746
- Testing
- Radiotherapy alone, Radiotherapy with cisplatin
- Where
- 5 sites in India, South Africa and 3 more
- Volunteers
- 322 people
- Sponsor
- International Atomic Energy Agency
Male Urogenital Diseases, Genital Diseases, Male
Office Based Transperineal Laser Ablation for Benign Prostatic Hyperplasia HYPERPLASIA
This study is set up as a phase I-II prospective, single center, interventional pilot study carried in Office setting under local anesthesia.
- Conditions
- Male Urogenital Diseases, Genital Diseases, Male, Prostatic Disease, Prostatic Hyperplasia
- Trial name
- NCT04760483
- Testing
- SoracteLite(TM) TPLA for BPH
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Urological Research Network, LLC
Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma
Tislelizumab and Radiotherapy for Recurrent Cervical Cancer
This study is a prospective, multicenter, phase II clinical trial to evaluate the efficacy and safety of albumin-bound paclitaxel plus bevacizumab for platinum-resistant recurrent epithelial ovarian cancer.
- Conditions
- Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma, Radiotherapy
- Trial name
- NCT05310383
- Testing
- Tislelizumab plus radiotherapy
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Lei Li
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.